Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SKL35501 |
| Synonyms | |
| Therapy Description |
SKL35501 consists of a neurotensin receptor 1 (NTSR1) ligand labeled with Actinium-225, which may deliver radiotherapeutic to NTSR1-expressing cells, leading to tumor cell death (Cancer Res (2026) 86 (7_Supplement): 5817). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SKL35501 | SKL 35501|SKL-35501 | SKL35501 consists of a neurotensin receptor 1 (NTSR1) ligand labeled with Actinium-225, which may deliver radiotherapeutic to NTSR1-expressing cells, leading to tumor cell death (Cancer Res (2026) 86 (7_Supplement): 5817). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07812805 | Phase I | SKL35501 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | Recruiting | USA | 1 |